AI Summary
The text discusses the potential benefits of using molecular subtype-based treatment optimization for triple-negative breast cancer patients. Phase 3 trials are currently being conducted to evaluate the efficacy of this approach.
These findings highlight the potential clinical benefits of using molecular subtype-based treatment optimisation in patients with triple-negative breast cancer, suggesting a path for further clinical investigation. Phase 3 randomised clinical trials assessing the efficacy of subtyping-based regimens are now underway.